Well Referenced

Tag: first-line treatment

Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection

This 2016 observational retrospective study compared the efficacy of quadruple concomitant non-bismuth therapy (amoxicillin, clarithromycin, metronidazole, and a proton pump inhibitor) versus classical triple therapy (amoxicillin, clarithromycin, and a proton pump inhibitor) as first-line treatments for Helicobacter pylori infection. Among 510 patients treated between January 2012 and May 2014, the

Read More »
June 26, 2025 No Comments

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

This network meta-analysis synthesized data from nine phase III randomized controlled trials to assess the relative efficacy of various first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). The study found that combinations of immune checkpoint inhibitors (ICIs) and anti-VEGF agents, particularly atezolizumab plus bevacizumab, demonstrated the most favorable outcomes in

Read More »
June 26, 2025 No Comments

Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)

This 2017 randomized, double-blind, placebo- and celecoxib-controlled trial evaluated the efficacy and safety of pharmaceutical-grade chondroitin sulfate (CS) 800 mg/day in 604 patients with symptomatic knee osteoarthritis over 6 months. CS demonstrated a statistically significant reduction in pain (−42.6 mm on VAS) and improvement in function (−4.7 on Lequesne Index)

Read More »
June 26, 2025 No Comments